| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Section of Experimental Pathology, Departments of Cell Biology [R. F. T., M. E. V., E. L. B., H. L. M.] and Pathology [H. L. M.], Mayo Clinic, Foundation and Medical School, Rochester, Minnesota 55905
Multiple transforming growth factors (TGFs) have been isolated from the serum-free conditioned media and acid-ethanol cell extracts of nontransformed AKR-2B and chemically transformed AKR-MCA mouse cells. The TGF activity was analyzed using Bio-Gel P-60 chromatography in 1 M acetic acid and tested for colony-stimulating activity in soft agar using AKR-2B, AKR-2B (clone 84A), NRK, and AKR-MCA cells as indicators. Both intracellular and extracellular TGF activity from AKR-MCA and AKR-2B cells show a major peak of AKR-2B and epidermal growth factor-potentiated NRK colony-stimulating activity that coelute in the 13,000 ± 2,000 molecular weight region. In the 24,000 ± 7,000 molecular weight range, AKR-MCA cells produce intracellular and extracellular NRK colony-stimulating activity that is not potentiated by epidermal growth factor, while the intracellular and extracellular NRK colony-stimulating activity produced by AKR-2B cells requires added epidermal growth factor for colony formation. Also important in determining the growth and morphological characteristics of a cell line, besides the production of a TGF, is the ability of a cell to respond to TGF activity. We have shown that the transformed AKR-MCA cells form more colonies than AKR-2B cells in response to certain TGF activities. This suggests that the increased responsiveness of AKR-MCA cells to TGFs may be important in determining its phenotype.
1 Supported by USPHS Grant CA 27217 awarded by the National Cancer Institute, Department of Health and Human Services.
2 To whom requests for reprints should be addressed.
Received 8/ 2/82. Accepted 1/ 4/83.
This article has been cited by other articles:
![]() |
R. Heimark, D. Twardzik, and S. Schwartz Inhibition of endothelial regeneration by type-beta transforming growth factor from platelets Science, September 5, 1986; 233(4768): 1078 - 1080. [Abstract] [PDF] |
||||
![]() |
M. Sporn, A. Roberts, L. Wakefield, and R. Assoian Transforming growth factor-beta: biological function and chemical structure Science, August 1, 1986; 233(4763): 532 - 534. [Abstract] [PDF] |
||||
![]() |
R. Nordan and M Potter A macrophage-derived factor required by plasmacytomas for survival and proliferation in vitro Science, August 1, 1986; 233(4763): 566 - 569. [Abstract] [PDF] |
||||
![]() |
B. Sugarman, B. Aggarwal, P. Hass, I. Figari, M. Palladino Jr, and H. Shepard Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro Science, November 22, 1985; 230(4728): 943 - 945. [Abstract] [PDF] |
||||
![]() |
R. Tucker, G. Shipley, H. Moses, and R. Holley Growth inhibitor from BSC-1 cells closely related to platelet type beta transforming growth factor Science, November 9, 1984; 226(4675): 705 - 707. [Abstract] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |